FOR IMMEDIATE RELEASE
December 23, 2020
STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF
Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison
Phone: (919) 903-2057
MOST FAVORED NATION: TEMPORARY RESTRAINING ORDER ISSUED
NCODA has been in opposition of the Most Favored Nation (MFN) model for Medicare patients since it was announced late last month. The model would negatively affect patient access to Part B drugs – the anti-cancer (oral and infused) treatments that are administered in oncology practices.
Today, it was announced that US District Court Judge Catherine Blake (Maryland) issued a two-week temporary restraining order (TRO) which delays the implementation of the MFN model. The two-week reprieve allows the court time to consider implementing a preliminary injunction against the MFN model.
This mandatory 7-year payment model would establish reimbursement to providers based on an MFN price for the 50 highest cost Part B drugs. The MFN price would be phased in to replace the current ASP reimbursement model and would be based on international pricing from other similar countries.
This model would create a potentially insurmountable challenge for oncology practices, and it would hurt the people who matter most – the patients. NCODA continues to oppose this model and will monitor and update our membership as progress is made on this decision.
Michael Reff, RPh, MBA
Founder & Executive Director | NCODA, Inc.
Read the full release HERE.